Drugs / Lemuteporfin
Lemuteporfin
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01830764 | Apr → Jun 2013 | acne | Dermira, Inc. | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT01490736 | Dec 2011 → Mar 2013 | acne | Dermira, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT00077012 | Mar 2003 → May 2005 | benign prostatic hyperplasia | QLT Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00116571 | May 2005 → Dec 2006 | benign prostatic hyperplasia | QLT Inc. | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lemuteporfin | “The purpose of this study is assess the safety and tolerability of lemuteporfin topical solution (LTS) with exposure to red light (PDT), when applied to the backs of healthy volunteers.” NCT01830764 ↗ |
| Known as | Lemuteporfina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107756 ↗ |
| Known as | Lemuteporfine | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107756 ↗ |
| Known as | LTS | “The purpose of this study is assess the safety and tolerability of lemuteporfin topical solution (LTS) with exposure to red light (PDT), when applied to the backs of healthy volunteers.” NCT01830764 ↗ |
| Known as | QLT0074 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00077012 ↗ |
| Modality | Small molecule | — CHEMBL2107756 ↗ |
| Route | Other | “injected transurethrally into the prostate” NCT00077012 ↗ |